Navigation Links
Halozyme Therapeutics To Present At The Piper Jaffray Healthcare Conference
Date:11/26/2013

SAN DIEGO, Nov. 26, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) will be presenting at the Piper Jaffray Healthcare Conference in New York on Tuesday, December 3, 2013 at 12:00 p.m. ET/9:00 a.m. PT. Gregory I. Frost, Ph.D., President and Chief Executive Officer, Halozyme Therapeutics, will provide a corporate overview.

(Logo:  http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

The presentation will be webcast through the "Investors" section of Halozyme's corporate website at www.halozyme.com, and a recording will be made available for 90 days following the event. To access the live webcast, please log on to Halozyme's website approximately 15 minutes prior to the presentation to register and download any necessary audio software.

About Halozyme
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, which increase the absorption and dispersion of biologics, drugs and fluids. Halozyme's pipeline addresses therapeutic areas, including diabetes, oncology and dermatology that have significant unmet medical need. The Company markets Hylenex® recombinant (hyaluronidase human injection) and has partnerships with Roche, Pfizer, Baxter, and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at www.halozyme.com and follow u
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Halozyme Therapeutics To Present At The Credit Suisse Healthcare Conference
2. Halozyme to Host Third Quarter 2013 Financial Results Conference Call
3. SWOG Initiates Randomized Phase 2 Clinical Trial of Halozymes PEGPH20 in Combination with modified FOLFIRINOX for Advanced Pancreatic Cancer
4. Halozyme Presents PEGPH20 Phase 1b Clinical Trial Data at European Cancer Congress 2013
5. Commercial Launch of Herceptin SC in EU Triggers Milestone Payment to Halozyme from Roche
6. Halozyme Therapeutics To Present At The BioCentury Newsmakers In The Biotech Industry Conference
7. Halozyme to Present New Data on PEGPH20 in Pancreatic Cancer at European Cancer Congress
8. Halozyme Announces Roche Receives Marketing Authorization for Herceptin SC in European Union
9. Halozyme Reports Second Quarter 2013 Financial Results
10. Halozyme Provides Update on ViroPharma Phase 2 Trial of Subcutaneous Cinryze (C1 Esterase Inhibitor [Human]) Formulation with rHuPH20
11. Halozyme to Host Second Quarter 2013 Financial Results Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... NEW YORK , Aug. 20, 2014 /PRNewswire/ ... report is available in its catalogue: ... U.S. IVD Industry http://www.reportlinker.com/p01618927/The-Impact-of-Healthcare-Reform-PPACA-On-the-US-IVD-Industry.html ... Care Act" (H.R. 3590) is complex legislation that ... many of its provisions are beginning to take ...
(Date:8/20/2014)... , Aug. 20, 2014 Reportbuyer.com has added ... Defibrillators Industry https://www.reportbuyer.com/product/98394/Global-Cardiac-Defibrillators-Industry.html ... in US$ Million by the following Product Segments: Implantable/Internal ... comprehensive analytics for the US, Canada ... , Asia-Pacific , ...
(Date:8/20/2014)... , August 20, 2014 ... market report titled "Monochloroacetic Acid (MCA) Market for Cellulosics, ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast ... valued at USD 817.1 million in 2013 and is ... at a CAGR of 3.6% during the forecast period ...
Breaking Medicine Technology:The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 2The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 3The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 4The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 5The Impact of Healthcare Reform (PPACA) On the U.S. IVD Industry 6Global Cardiac Defibrillators Industry 2Global Cardiac Defibrillators Industry 3Global Cardiac Defibrillators Industry 4Global Cardiac Defibrillators Industry 5Global Cardiac Defibrillators Industry 6Global Cardiac Defibrillators Industry 7Global Cardiac Defibrillators Industry 8Global Cardiac Defibrillators Industry 9Global Cardiac Defibrillators Industry 10Global Cardiac Defibrillators Industry 11Global Cardiac Defibrillators Industry 12Global Cardiac Defibrillators Industry 13Global Cardiac Defibrillators Industry 14Global Cardiac Defibrillators Industry 15Global Cardiac Defibrillators Industry 16Global Cardiac Defibrillators Industry 17Global Cardiac Defibrillators Industry 18Global Cardiac Defibrillators Industry 19Global Cardiac Defibrillators Industry 20Global Monochloroacetic Acid (MCA) Market is Expected to Reach USD 1,046.7 million by 2020: Transparency Market Research 2Global Monochloroacetic Acid (MCA) Market is Expected to Reach USD 1,046.7 million by 2020: Transparency Market Research 3Global Monochloroacetic Acid (MCA) Market is Expected to Reach USD 1,046.7 million by 2020: Transparency Market Research 4
... July 30 Peptimmune, Inc. a privately,held ... US Patent Number,7,381,790 (the ,790 patent) which ... peptide copolymer for the treatment of autoimmune ... Phase Ib multiple-ascending dose,double-blind, placebo-controlled randomized study ...
... issues a review of,Generex Biotechnology Corporation (Nasdaq: ... Platform, Sets the Tone as Best in,Class Followed ... This review is available at website: http://www.scimitarequity.com ... development, and commercialization,of drug delivery systems and technologies. ...
Cached Medicine Technology:Peptimmune Announces Grant of United States Patent for PI-2301 Peptide Copolymer for Multiple Sclerosis 2Peptimmune Announces Grant of United States Patent for PI-2301 Peptide Copolymer for Multiple Sclerosis 3Generex Biotechnology Corporation Initiation Coverage Review Issued By Scimitar Equity, LLC 2
(Date:8/20/2014)... Loss of brain cells that act as a "sleep ... falling and staying asleep, a new study suggests. ... and often results in nighttime confusion and wandering, according ... the Rush Memory and Aging Project, which includes nearly ... being followed until death, at which point their brains ...
(Date:8/20/2014)... HealthDay Reporter WEDNESDAY, Aug. 20, 2014 ... been an option, but a new study shows that only ... common reasons women didn,t undergo reconstruction was that they felt ... they were focused on their cancer treatment," said lead researcher ... Kettering Cancer Center, in New York City. Also common ...
(Date:8/20/2014)... one of the most persistent and deadliest infectious diseases ... each year. , Scientists who study tuberculosis have long ... spread from humans in Africa to seals and sea ... transmitted it to Native people there before Europeans landed ... Reveal Seals as a Source of New World Human ...
(Date:8/20/2014)... Salt Lake City, Utah (PRWEB) August 20, 2014 ... the Inc. 500’s 2014 list of the nation’s fastest growing ... overall growth in the health care sector. Connexion Point is ... specializes in contact centers in Medicare and Medicaid, and its ... in the nation. Connexion Point employs 1,000 people and has ...
(Date:8/20/2014)... YORK, NY (August 20, 2014) Research from Columbia ... critical role in stomach cancer growth and that blocking ... an effective treatment for the disease. The study was ... in collaboration with Duan Chen, MD, PhD, in Norway ... Translational Medicine . , "Scientists have long observed that ...
Breaking Medicine News(10 mins):Health News:Seniors' Sleep Woes May Be Linked to Loss of Brain Cells 2Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 2Health News:Many Women Who Have Mastectomy Don't Get Breast Reconstruction: Study 3Health News:New research shows seals and sea lions likely spread tuberculosis to humans 2Health News:New research shows seals and sea lions likely spread tuberculosis to humans 3Health News:With 3943.8% Growth, Connexion Point, a Leader in Contact Centers for Health Care, Ranks 86th on the Inc. 500 List as One of the Nation’s Fastest Growing Companies 2Health News:Severing nerves may shrink stomach cancers: Botox injections slow growth of tumors in mice 2
... (Nasdaq: CYNO ), a leading developer and ... systems, today announced financial results for the three and ... Results Consistent with Cynosure,s January 15, 2009 announcement, ... were $25.5 million, reflecting the effect of deteriorating global ...
... Feb. 10 Novasys Medical, Inc., a developer of ... one of the nation,s leading health insurers with over ... treatment for stress urinary incontinence (SUI) in non-pregnant women ... undergo surgery for their condition. According to Aetna,s updated ...
... Kit Offers Extensive Enrollment Information and Insights into ... Feb. 10 HealthLeaders-InterStudy , a leading ... District Survival Kit designed to provide pharmaceutical sales ... and analysis that drives innovative sales strategy development.Each ...
... quarter decline in procedure volume rate shows signs of ... 48% Provides near-term financial outlook CINCINNATI, Feb. 10 ... LCAV ), a leading provider of laser vision correction ... financial and operating results for the three and 12 ...
... OSF HealthCare and Seattle Children,s Hospital among the ... software suiteCLEVELAND, Feb. 10 Healthcare organizations ... healthy lifestyle. Now, hospitals and health systems are ... preaching. Paper medical records cause costly errors, potentially ...
... AHPI ) reported that its net income for ... or zero cents per share in the,prior year period, to ... per,share, primarily because of lower sales volume in the current ... the second quarter fell about 8 percent, or almost $1.1,million, ...
Cached Medicine News:Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 2Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 3Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 4Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 5Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 6Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 7Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 8Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 9Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 10Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 11Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 12Health News:Cynosure Reports Financial Results for the Fourth Quarter and Full Year 2008 13Health News:Aetna Now Covers Novasys Medical's Renessa(R) Treatment for Incontinence in Women 2Health News:HealthLeaders-InterStudy Offers District Survival Kit to Arm Pharmaceutical Sales Teams With Local-Level Managed Care Market Intelligence 2Health News:LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results 2Health News:LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results 3Health News:LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results 4Health News:LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results 5Health News:LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results 6Health News:LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results 7Health News:LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results 8Health News:LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results 9Health News:LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results 10Health News:LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results 11Health News:LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results 12Health News:LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results 13Health News:LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results 14Health News:LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results 15Health News:LCA-Vision Announces Fourth Quarter and Full Year 2008 Financial Results 16Health News:OnBase is the Choice for a Growing Number of Healthcare Organizations 2Health News:OnBase is the Choice for a Growing Number of Healthcare Organizations 3Health News:Allied Healthcare Reports Second Quarter Loss 2Health News:Allied Healthcare Reports Second Quarter Loss 3Health News:Allied Healthcare Reports Second Quarter Loss 4Health News:Allied Healthcare Reports Second Quarter Loss 5
... Our breadth of infectious disease ELISA ... field. With standard assay protocols for faster ... Disease ELISA products provide increased reliability and ... includes antibody detection assays for a wide ...
... of infectious disease ELISA products make us ... assay protocols for faster integration into the ... provide increased reliability and run-to-run consistency. Our ... assays for a wide range of serological ...
... Our breadth of infectious disease ELISA ... field. With standard assay protocols for faster ... Disease ELISA products provide increased reliability and ... includes antibody detection assays for a wide ...
... of infectious disease ELISA products make us ... assay protocols for faster integration into the ... provide increased reliability and run-to-run consistency. Our ... assays for a wide range of serological ...
Medicine Products: